October 13, 2022 article Open access Small molecule inhibitors targeting the cancers MedComm DOI: 10.1002/mco2.181 Full text (OA) OpenAlex Authors 0 Author list not loaded yet. Cited by 2 stored of 186 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access Preclinical pancreatic cancer mouse models for treatment with small molecule inhibitors: a systematic review and meta-analysis 2025 Scientific Reports review Medicine Pancreatic and Hepatic Oncology Research Open access 2 citations A patient-centric knowledge graph approach to prioritize mutants for selective anti-cancer targeting 2024 bioRxiv (Cold Spring Harbor Laboratory) preprint Biochemistry, Genetics and Molecular Biology Bioinformatics and Genomic Networks Open access 0 citations 2 results References 6 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial 2020 The Lancet Oncology article Medicine Gastrointestinal Tumor Research and Treatment Open access cited by 48 patents 430 citations Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial 2020 The Lancet Haematology article Medicine Lymphoma Diagnosis and Treatment Open access cited by 2 patents 345 citations Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib 2020 Journal of Clinical Oncology article Medicine Gastrointestinal Tumor Research and Treatment Open access 91 citations Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer 2020 British Journal of Cancer article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access 57 citations Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study 2021 Clinical Cancer Research article Medicine Gastrointestinal Tumor Research and Treatment Open access 46 citations Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study 2021 Journal of Hematology & Oncology article Medicine Lymphoma Diagnosis and Treatment Open access 16 citations 6 results